China SXT Pharmaceuticals Shareholders’ Equity Growth & History (SXTC)

China SXT Pharmaceuticals's shareholders’ equity was $29.7M for fiscal 2026.

View full China SXT Pharmaceuticals company overview

China SXT Pharmaceuticals annual shareholders’ equity history

China SXT Pharmaceuticals annual shareholders’ equity

Fiscal yearPeriod endedShareholders’ equityChangeGrowth
20262026-03-31$29.7M$14.3M+92.41%
20252025-03-31$15.4M$1.5M+10.83%
20242024-03-31$13.9M−$760,849−5.18%
20232023-03-31$14.7M−$1.4M−8.65%
20222022-03-31$16.1M$121,682+0.76%
20212021-03-31$16.0M$6.6M+69.78%
20202020-03-31$9.4M−$1.7M−15.36%
20192019-03-31$11.1M$7.8M+238.06%
20182018-03-31$3.3M$1.4M+77.36%
20172017-03-31$1.9M

China SXT Pharmaceuticals shareholders’ equity trends

Over the last five fiscal years, China SXT Pharmaceuticals's shareholders’ equity increased from $16.0M to $29.7M, a change of $13.7M. The latest reported quarter, Q4 2026, shows $29.7M.

About the metric

What shareholders’ equity means

Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.

Calculation and source

SEC-reported shareholders’ equity

TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review China SXT Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about SXTC yet. Start the conversation.

Write the first post